Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Methodology|Interests|Funding|Corrections
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Trial abstract · §5

STRIDE — citing documents

Every Institute document that draws on this record.

Document identifier
CEI-TR-0012/5
Series
Trial abstract
Version
1.1
Published
08 Mar 2025
Last reviewed
08 Dec 2025
Next review
08 Dec 2027
Identifier
10.71829/cei.trial.12
Certainty
Moderate
Cycle
2025 Q1
Phase
Phase 3
Status
Reported

§5Citing documents

This page records every Institute document that draws on STRIDE. A trial abstract is a node in the document set rather than a leaf: it is cited by the monographs that use its estimate and by the syntheses that include it, and those citations are listed here so that the flow of an estimate through the document set can be followed in both directions.

§5.1Monograph evidence extracts

Table 7. Monograph evidence extracts that draw on this trial.

CompoundIndicationCertainty there
SemaglutidePeripheral arterial disease with intermittent claudicationModerate

§5.2Evidence syntheses

Table 8. Evidence syntheses that include this trial among their contributing studies.

SynthesisReview typeCertainty
Gastrointestinal adverse events with incretin receptor agonistsSafety reviewHigh
Oral compared with injectable presentations of glucagon-like peptide-1 receptor agonismNetwork meta-analysisModerate
Kidney outcomes with incretin receptor agonists in chronic kidney diseaseIntervention reviewHigh
Completeness of certificates of analysis in the research-supply channelAnalytical evidence reviewModerate
Counter-ion content and its effect on delivered peptide massAnalytical evidence reviewHigh
Analytical surveys of unregulated peptide supplyAnalytical evidence reviewLow
The consequences of a wholly sponsor-generated evidence baseMethodological reviewModerate
The rodent thyroid C-cell signal and its human relevanceSafety reviewLow
Reconstitution practice and delivered doseAnalytical evidence reviewModerate
Acute pancreatitis with incretin-based therapiesSafety reviewModerate
Bacterial endotoxin in research-supply peptide presentationsAnalytical evidence reviewLow
Tirzepatide compared with semaglutide in type 2 diabetesIntervention reviewHigh
Dependence of reported purity on the analytical methodAnalytical evidence reviewHigh
In-use stability of reconstituted peptide solutionsAnalytical evidence reviewModerate
Semaglutide in type 2 diabetes mellitus: effect on the anchor outcomeIntervention reviewHigh
Semaglutide in type 2 diabetes mellitus: tolerability and discontinuationSafety reviewHigh
Semaglutide in type 2 diabetes mellitus: durability of effectIntervention reviewHigh

§5.3Other records in the same programme

Table 9. Other records in the STRIDE — semaglutide in peripheral arterial disease.

RecordTypePhaseStatus
STRIDE-QOLProgramme record3Reported
STRIDE-REGIONAL-CNProgramme record3Reported
STRIDE-REGIONAL-JPProgramme record3Reported

§5.4Reference

The Institute holds no publication reference for this trial. Where a trial is real and its report has not been obtained, the record says so rather than citing a source it does not hold.

Compound Evidence Institute · CEI-TR-0012/5 · https://compoundevidence.com/trials/stride/citations/ · retrieved 30 July 2026
Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.